RESUMEN
The most important strategies for molecular imaging are presented. Processes can now be imaged in vitro and in vivo at the molecular level with the help of modern procedures such as SPECT, PET, MRI, and highly developed optical methods. The ability to view the expression of genes, the pharmacokinetics of gene therapy vectors, of therapeutic DNA, and of classical pharmacons in vivo opens up completely new perspectives for the research on, diagnosis of, and therapy for diseases. The current status of these developments are described, potential fields of use and possibilities for further development are outlined.
Asunto(s)
Diagnóstico por Imagen , Expresión Génica/fisiología , Terapia Genética , Biología Molecular , Genes Reporteros/genética , Humanos , Imagen por Resonancia Magnética , Tomografía Computarizada de Emisión , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
Retroviral vectors derived from amphotropic murine leukemia viruses (MLV) mediate gene transfer into almost all human cells and are thus not suitable for in vivo applications in gene therapy in which cell-specific gene delivery is required. We and others recently reported the generation of MLV-derived vectors pseudotyped by variants of the envelope glycoproteins (Env) of human immunodeficiency virus type 1 (HIV-1), thus displaying the CD4-dependent tropism of the parental lentivirus (Mammano et al., 1997, J. Virol. 71, 3341-3345; Schnierle et al., 1997, Proc. Natl. Acad. Sci. USA 76, 8640-8645). However, because of their HIV-1-derived envelopes these vectors are neutralized by HIV-specific antibodies present in some infected patients. To circumvent this problem, we pseudotyped MLV capsid particles with variants of Env proteins derived from the apathogenic simian immunodeficiency virus (SIVagm) of African green monkeys (AGM; Chlorocebus pygerythrus). Truncation of the C-terminal domain of the transmembrane protein was found to be necessary to allow formation of infectious pseudotype vectors. These [MLV(SIVagm)] vectors efficiently transduced various human CD4-expressing cell lines using the coreceptors CCR5 and Bonzo to enter target cells. Moreover, they were resistant to neutralization by antibodies directed against HIV-1. Therefore, [MLV(SIVagm)] vectors will be useful to study the mechanisms of SIVagm cell entry and for the selective gene transfer into CD4+ T-cells of AIDS patients.
Asunto(s)
Linfocitos T CD4-Positivos/metabolismo , Vectores Genéticos/genética , Infecciones por VIH/sangre , Sueros Inmunes/inmunología , Virus de la Leucemia Murina/genética , Receptores Acoplados a Proteínas G , Secuencia de Aminoácidos , Animales , Linfocitos T CD4-Positivos/virología , Línea Celular , Chlorocebus aethiops , ADN Recombinante , ADN Viral/genética , Regulación de la Expresión Génica , Genes env/genética , Variación Genética , Vectores Genéticos/inmunología , Células Gigantes/virología , Células HeLa , Humanos , Células Jurkat , Virus de la Leucemia Murina/inmunología , Ratones , Datos de Secuencia Molecular , Pruebas de Neutralización , Receptores CCR5/fisiología , Receptores CXCR6 , Receptores de Quimiocina , Receptores de Citocinas/fisiología , Receptores Virales/fisiología , Retroviridae/genética , Retroviridae/inmunología , Virus de la Inmunodeficiencia de los Simios/genética , Células Tumorales CultivadasRESUMEN
The term molecular radiology intermediate region between radiological imaging and interventional radiology on the one side and molecular biology on the other. In the field of imaging methods are currently being developed by which molecular processes, i.e., gene expression and protein function, can be visualized in vivo. These techniques open new perspectives for research and clinical diagnosis and will be presented in the second part of this review. The present part provides a survey of current developments in gene therapy from a radiological point of view and highlights the part that our specialty may play in this field.
Asunto(s)
Terapia Genética , Radiografía , Animales , Terapia Genética/métodos , Humanos , Neoplasias/terapia , Enfermedades Vasculares/terapiaRESUMEN
The successful application of human gene therapy protocols on a broad clinical basis will depend on the availability of in vivo cell-type-specific gene delivery systems. We have developed retroviral vector particles, derived from spleen necrosis virus (SNV), that display the antigen binding site of an antibody on the viral surface. Using retroviral vectors derived from SNV that displayed single-chain antibodies (scAs) directed against a carcinoembryonic antigen-cross-reacting cell surface protein, we have shown that an efficient, cell-type-specific gene delivery can be obtained. In this study, we tested whether other scAs displayed on SNV vector particles can also lead to cell-type-specific gene delivery. We displayed the following scAs on the retroviral surface: one directed against the human cell surface antigen Her2neu, which belongs to the epidermal growth factor receptor family; one directed against the stem cell-specific antigen CD34; and one directed against the transferrin receptor, which is expressed on liver cells and various other tissues. We show that retroviral vectors displaying these scAs are competent for infection in human cells which express the antigen recognized by the scA. Infectivity was cell type specific, and titers above 10(5) CFU per ml of tissue culture supernatant medium were obtained. The density of the antigen on the target cell surface does not influence virus titers in vitro. Our data indicate that the SNV vector system is well suited for the development of a large variety of cell-type-specific targeting vectors.
Asunto(s)
Anticuerpos/genética , Técnicas de Transferencia de Gen , Vectores Genéticos , Retroviridae/genética , Retroviridae/inmunología , Animales , Antígenos CD34/inmunología , Secuencia de Bases , Sitios de Unión de Anticuerpos/genética , Antígeno Carcinoembrionario/inmunología , Línea Celular , Cartilla de ADN/genética , Perros , Humanos , Plásmidos/genética , Receptor ErbB-2/inmunología , Receptores de Transferrina/inmunología , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunologíaRESUMEN
CD4-expressing T cells in lymphoid organs are infected by the primary strains of HIV and represent one of the main sources of virus replication. Gene therapy strategies are being developed that allow the transfer of exogenous genes into CD4(+) T lymphocytes whose expression might prevent viral infection or replication. Insights into the mechanisms that govern virus entry into the target cells can be exploited for this purpose. Major determinants of the tropism of infection are the CD4 molecules on the surface of the target cells and the viral envelope glycoproteins at the viral surface. The best characterized and most widely used gene transfer vectors are derived from Moloney murine leukemia virus (MuLV). To generate MuLV-based retroviral gene transfer vector particles with specificity of infection for CD4-expressing cells, we attempted to produce viral pseudotypes, consisting of MuLV capsid particles and the surface (SU) and transmembrane (TM) envelope glycoproteins gp120-SU and gp41-TM of HIV type 1 (HIV-1). Full-length HIV-1 envelope glycoproteins were expressed in the MuLV env-negative packaging cell line TELCeB6. Formation of infectious pseudotype particles was not observed. However, using a truncated variant of the transmembrane protein, lacking sequences of the carboxyl-terminal cytoplasmic domain, pseudotyped retroviruses were generated. Removal of the carboxyl-terminal domain of the transmembrane envelope protein of HIV-1 was therefore absolutely required for the generation of the viral pseudotypes. The virus was shown to infect CD4-expressing cell lines, and infection was prevented by antisera specific for gp120-SU. This retroviral vector should prove useful for the study of HIV infection events mediated by HIV-1 envelope glycoproteins, and for the targeting of CD4(+) cells during gene therapy of AIDS.